Submission of Integrated Annual Report 2025-26

August 3, 2026 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Phiroz Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (E), 25th floor, Dalal Street, MUMBAI -400 051 MUMBAI -400 001 Company Code No. AUROPHARMA Company Code No. 524804 Dear Sir / Madam, Sub: Notice of 39th Annual General Meeting and Annual Report for the financial year 2025-26. Further to our letter dated July 29, 2026 intimating the date of 39th Annual General Meeting (AGM) of the Members of the Company and pursuant to Regulation 34 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015, please find enclosed Integrated Annual Report for the financial year 2025-26 along with Notice of 39th AGM of the Company to be held on Thursday, August 27, 2026 at 3:30 p.m. IST through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM") which is being sent to the shareholders of the Company through electronic mode. For those shareholders whose email IDs are not registered with the Company / RTA/ Depositories, a letter containing the weblink and path will be sent to access the Notice of the 39th Annual General Meeting and Integrated Annual Report for the financial year 2025-26. The Annual Report containing the Notice is also being uploaded on the Company's website https://www.aurobindo.com/investors/results-reports-presentations/annual-reports/. Further, an e-voting facility for the AGM will be made available to all the Members of the Company. The date and time of remote e- voting facility are as under: Date and time of commencement of remote e-voting Monday, August 24, 2026, at 9:00 a.m. (IST) Date and time of end of remote e-voting Wednesday, August 26, 2026, at 5:00 p.m. (IST) Cut-off date for determining the eligibility to vote by Thursday, August 20, 2026 electronic means or in the AGM Please take the information on record. Thanking you, Yours faithfully, For AUROBINDO PHARMA LIMITED B. Adi Reddy Company Secretary Encl: as above. Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044. Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500038 Telangana,India Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833 Email: info@aurobindo.com Website: www.aurobindo.com Aurobindo Pharma Limited Integrated Annual Report 2025-26 Decades of Purpose Progress. Strength today, Momentum ahead. We take you About the report through... At Aurobindo Pharma Limited, we are pleased to present our Integrated Annual Report for FY26, offering a comprehensive overview of our performance, strategic priorities, 01 About the Report governance practices and long-term value creation journey. Introduction 02 Four Decades of Purpose & Progress Our integrated reporting and corporate functions to ensure a Our Strategic Priorities 04 Milestones that Shaped Our Progress approach provides stakeholders holistic and transparent representation S1 Strengthening Global 06 How We Performed with a balanced and connected of our operations, risks, opportunities Manufacturing & Supply view of our financial and non- and long-term priorities. Chain Resilience financial performance, including SCOPE AND BOUNDARY S2 Accelerating Global manufacturing excellence, product Market Expansion development, sustainability, The report covers Aurobindo Pharma 08 10 About Aurobindo Pharma 26 Vice Chairman & Corporate people practices and stakeholder Limited’s standalone and consolidated S3 Building A Diversified & 14 Our Global Footprint Managing Director's Message engagement. It also outlines operations, including manufacturing Specialty-Led Product Portfolio overview 16 Our Business Segments 30 Awards and Accolades how we are building capabilities facilities, research and development S4 Creating Future-Ready across complex and differentiated centres, commercial operations and Growth Platforms In Biologics 20 Therapeutic Areas pharmaceutical segments while corporate functions across geographies, & Biosimilars scaling responsibly across unless stated otherwise. Sustainability- S5 Expanding Capabilities In global markets. related disclosures primarily cover Respiratory, Dermatology & manufacturing units, R&D centres and 32 This report is organised through Specialty Therapies Through 34 Business Model 50 Materiality Assessment corporate offices across geographies How we the six capitals framework, namely Strategic Collaborations based on operational relevance and 36 Operating Environment 58 Risk Management Financial, Manufacturing, Intellectual, create value data availability. 40 Strategic Priorities 70 Governance Human, Social and Relationship, FORWARD-LOOKING and Natural Capital. It provides ASSURANCE AND DATA 44 Sustainability at the Core 74 Board of Directors STATEMENTS stakeholders with a balanced view RELIABILITY 48 Stakeholder Engagement of how we use, strengthen and Certain statements in this report may protect these capitals to create Financial information presented contain forward-looking perspectives sustained value. in this report is based on audited relating to the Company’s future financial statements. Non-financial business outlook, growth plans 76 REPORTING PERIOD and sustainability-related information and operating performance. Actual 78 Business Review 108 Social and Performance 90 Financial Capital Relationship Capital The report covers the financial year i rs e pco om rtip ni gle sd y sth tero mu sg , h fu i nn cte tir on na al l outcomes may differ materially due review 96 Manufactured Capital 116 Human Capital f ar no dm i nA cp luri dl e1 s, 2 m0 a2 t5 e t ro ia M l da er vc eh l o3 p1 m, 2 e0 n2 t6 s, r Te hv ei e nw os n -a fn ind a m nca ian la ig ne fom rmen at t v ioa nli d ha at sio n. t ro e gc uh la an tog re ys din e vm ela or pk met e c no tn s,d eit cio on ns o, m ic 100 Intellectual Capital 138 Natural Capital up to the date of approval by the been assured by a third party with factors and other external variables. Board of Directors on May 21, 2026. reasonable assurance in accordance Feedback and Contact with SEBI’s Business Responsibility REPORTING FRAMEWORKS and Sustainability Report (BRSR) We value stakeholder feedback 153 AND PRINCIPLES requirements. Where applicable, as an important input towards Statutory 154 Notice 223 Business Responsibility This report has been prepared in disclosures are reviewed in line with improving the quality, relevance and reports 170 Board’s Report & Sustainability Report alignment with the principles of statutory requirements and internal transparency of our reporting. For 211 Management Discussion 266 Report on Corporate Integrated Reporting Framework controls to ensure consistency, any queries or suggestions relating to and Analysis Governance as per International Integrated accuracy and reliability. this report, please write to: Reporting Council (IIRC), Global jvnreddy@aurobindo.com | REPORT NAVIGATION Reporting Initiative (GRI) and ir@aurobindo.com | To improve readability, this report relevant sections of EU Corporate Throughout this Integrated Annual uses a simple navigation system 294 Sustainability Reporting Directive Report, Aurobindo Pharma Limited is Financial 294 Standalone (CSRD). Relevant disclosures have across relevant sections: referred to as “Aurobindo Pharma”, “APL”, also been aligned with applicable statements 388 Consolidated statutory requirements, including Capitals “the Company”, “we”, “us” or “our” the Companies Act, 2013, SEBI (Listing Obligations and Disclosure Financial Manufacturing Requirements) Regulations and Business Responsibility and Sustainability Reporting Intellectual Human (BRSR) requirements. Scan the code to read the report on your The reporting process involves cross-functional participation across Social and hand-held screen Natural businesses, [Showing first 8,000 characters — download PDF for full document]